Table 3.
The general information of adult patients with primary HLH who received Allo-HSCT
| Patient’s number | P02 | P03 | P08 | P11 | P12 | P14 | P15 | P17 |
|---|---|---|---|---|---|---|---|---|
| donor origin | affinity | affinity | affinity | affinity | affinity | affinity | affinity | affinity |
| human leukocyte antigen (HLA) typing | 5/10 | 5/10 | 10/10 | 5/10 | 10/10 | 5/10 | 5/10 | 5/10 |
| stem cell type | PB | PB | PB | PB | PB | PB | PB | PB |
| pretreatment regimen | TBI/VP16/CTX | TBI/VP16 /Cy |
TBI/VP16/Cy | TBI/VP16 /CTX |
VP16/Bu/Cy | VP16/BU/FLU/ATG | TBI/VP-16/CTX | VP16/BU/ FLU/ATG |
| white blood cell viability (days) | + 10 | + 11 | +8 | + 12 | + 13 | + 10 | + 18 | + 15 |
| platelet engraftment time (days) | + 13 | + 12 | + 10 | + 13 | + 13 | + 15 | + 18 | + 15 |
| + 20 d donor chimerism rate | 100% | 99.6% | 100% | 100% | 99.04% | 100% | 100% | 97.78% |
| GVHD | III | – | – | I | – | – | – | – |
| pre-transplant EBV copy | 0 | 0 | 5.1 × 104 | 8.2 × 105 | 0 | 1.5 × 104 | 9.2 × 103 | 0 |
| post-transplant EBV copy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| prognosis | survival | survival | survival | death | survival | survival | survival | survival |